Status:

RECRUITING

The Impact of Emotional Stress on Immunotherapy Outcomes in Liver Cancer Patients: A Multi-Cohort Study

Lead Sponsor:

Guilin Medical University, China

Collaborating Sponsors:

the Affiliated hospital of Guilin medical university, China

Conditions:

HCC - Hepatocellular Carcinoma

Psychological Distress

Eligibility:

All Genders

18+ years

Brief Summary

The goal of this observational study is to learn if emotional distress affects how well liver cancer treatment works in people receiving immunotherapy. Emotional distress means feeling anxious or depr...

Detailed Description

This multi-center prospective cohort study investigates the relationship between emotional distress (ED) and treatment outcomes in patients receiving immune checkpoint inhibitor (ICI) therapy for hepa...

Eligibility Criteria

Inclusion

  • Cohort 1 (SOLACE-1):
  • Age ≥ 18 years
  • Able to complete psychological questionnaires
  • Child-Pugh liver function class A
  • ECOG performance status ≤ 1
  • Signed informed consent
  • Expected survival \> 3 months
  • Diagnosed with unresectable HCC by pathology or imaging
  • BCLC stage B or C
  • Has at least one measurable lesion (mRECIST)
  • About to receive first-line ICI treatment

Exclusion

  • Currently taking antidepressant or anti-anxiety medications
  • Previous diagnosis of psychiatric disorders
  • Concurrent malignancy
  • Unable to complete psychological assessments
  • Previous systemic anti-tumor therapy
  • Symptomatic brain metastases
  • Child-Pugh score \> 7
  • Cohort 2 (SOLACE-2):
  • Inclusion Criteria:
  • Age ≥ 18 years
  • Able to complete psychological questionnaires
  • Child-Pugh liver function class A
  • ECOG performance status ≤ 1
  • Signed informed consent
  • Expected survival \> 3 months
  • Pathologically confirmed HCC after curative surgery
  • Pathological stage II or III (AJCC 8th edition)
  • Will start adjuvant ICI therapy within 4-6 weeks after surgery
  • Expected survival \> 12 months

Key Trial Info

Start Date :

January 1 2025

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

December 31 2027

Estimated Enrollment :

700 Patients enrolled

Trial Details

Trial ID

NCT07141056

Start Date

January 1 2025

End Date

December 31 2027

Last Update

August 26 2025

Active Locations (5)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 2 (5 locations)

1

The Second Affiliated Hospital of Guangdong Medical University

Zhanjiang, Guangdong, China, 524000

2

The Affiliated Hospital of Guilin Medical University

Guilin, Guangxi, China, 541001

3

The Second Affiliated Hospital of Guilin Medical University

Guilin, Guangxi, China, 541001

4

Shaoyang Central Hospital

Shaoyang, Hunan, China, 422000